17 search results for: IL-13

Multifaceted Role of <b>IL-13</b> in Airway Remodeling

expert video

Multifaceted Role of IL-13 in Airway Remodeling

3 min

Type 2 Inflammation

Join Dr. Celeste Porsbjerg as she discusses on how IL-13 contributes to mucus plugging in asthma.

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and <b>IL-13</b>

expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

24 min

Pulmonology

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

expert video

Barrier disruption in AD and the development of environmental and food allergies

2 min

Dermatology

Dr Lio discusses the role of barrier disruption in AD, and the theory behind its association with environmental and food allergen sensitization.

expert video

Mucus Plugging as a Potential Target in Asthma Management

3 min

Type 2 Inflammation

Join Dr. Celeste Porsbjerg as she explores the mechanisms underlying mucus plugging development as mucociliary clearance. She explains how type 2 cytokines—particularly IL-13—impair this clearance mechanism, leading to mucus plugging, and worsened asthma outcomes.

expert video

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

5 min

Type 2 Inflammation

Join Dr. Celeste Porsbjerg as she discussed on how type 2 inflammation may lead to airway remodeling in asthma, exploring the pathophysiologic mechanisms, that ultimately lead to structural changes and irreversible loss of lung function

expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

20 min

Dermatology

This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.

Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

5 min

Pulmonology

Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma.

expert video

How type 2 cytokines can amplify inflammatory response in CSU

3 min

Dermatology

Dr. Thomos Casale explores the role of Th2 inflammation in CSU, highlighting the impact of IgE autoantibodies and the need for targeted therapies against Th2 cytokines.

expert video

Role of Type 2 Cytokines in Asthma and COPD

2 min

Type 2 Inflammation

Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.

expert video

Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients

2 min

Dermatology

Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.

expert video

Expert Interview with Dr Jason Hawkes

3 min

Dermatology

Join Dr. Hawkes as he discusses what burdens and challenges CSU patients might expect and help identify that there are immune functions responsible for their symptoms not an external cause.

videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

2 min

Dermatology

Learn more about how the exaggerated immune response due to chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region